Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex

X
Trial Profile

A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omadacycline (Primary)
  • Indications Nontuberculous mycobacterium infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Paratek Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2024 According to a Paratek Pharmaceuticals media release, Kevin Winthrop, M.D., M.P.H is the Principal Investigator in the study. And Analysis of study data is ongoing and the complete data from this study will be presented in the future and published in a peer-reviewed journal.
    • 08 Nov 2024 Results presented in the Paratek Pharmaceuticals Media Release.
    • 14 Oct 2024 According to a Paratek Pharmaceuticals media release, a new data from this study will be presented at IDWeek 2024, Oct. 16-19 at the Los Angeles Convention Center in Los Angeles, CA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top